Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 18

The DOI matches its Crossref record.

Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia

Olesovsky, Chris, Kapoor, Anil·2016·Therapeutic Advances in Urology
DOI 10.1177/1756287216650132
Open this paper in CoChat — free account

Abstract

Benign prostatic hyperplasia (BPH) is an age-related phenomenon associated with prostatic enlargement and bladder outlet obstruction that can cause significant lower urinary tract symptoms (LUTS). These LUTS have a negative impact on an individual’s quality of life, which is why treatment of symptomatic BPH has become a major priority. Although surgical interventions exist for treating BPH, pharmacological therapies are often preferred due to their minimal invasiveness and high degree of effectiveness. The three classes of drugs approved for treating BPH include α-blockers, 5-α-reductase inhibitors (5-ARIs) and phosphodiesterase 5 (PDE-5) inhibitors. Individually, each class of drug has been studied and shown to improve symptom relief through a variety of different mechanisms. A more recent focus has been on the development of combinatorial therapies that combine classes of drugs in order to provide maximal benefit. The mTOPS and CombAT studies were the first of their kind to examine whether the combination of 5-ARIs and α-blockers was more effective than monotherapy alone. Both studies found similar results in that the combinatorial therapy was superior to monotherapy. Over the last decade other combinatorial therapies have been at the forefront of investigation. One in particular is the combination of tadalafil, a PDE-5 inhibitor, with finasteride, a 5-ARI. Studies have shown that the combination of tadalafil and finasteride is a safe, effective, and well tolerated treatment for BPH. Evidence suggests that this combination may be particularly effective in reducing treatment-related sexual adverse events associated with 5-ARI treatments. The following review will explore in detail the current evidence surrounding treatment of BPH LUTS using tadalafil and finasteride.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1756287216650132

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 78

  1. 10.1016/S0090-4295(99)80291-X · DOI
  2. 10.1016/S0090-4295(97)00185-4 · DOI
  3. 10.1097/01.ju.0000139539.94828.29 · DOI
  4. 10.1016/S0022-5347(01)66780-6 · DOI
  5. 10.1159/000020181 · DOI
  6. 10.1056/NEJMoa053085 · DOI · Paper page
  7. 10.1016/S0022-5347(17)49698-4 · DOI
  8. 10.1186/1477-7525-7-55 · DOI
  9. 10.1016/S0090-4295(99)00593-2 · DOI
  10. 10.1016/S0302-2838(03)00358-0 · DOI
  11. Brock G., 2003, Can J Urol, 10, 17
  12. Carlin J., 1992, Drug Metab Dispos, 20, 148, 10.1016/S0090-9556(25)08559-9 · DOI
  13. 10.1016/j.juro.2013.09.059 · DOI
  14. 10.1016/j.eururo.2010.10.046 · DOI
  15. 10.1016/S0735-1097(98)00656-1 · DOI · Paper page
  16. 10.1016/j.clinthera.2009.09.015 · DOI
  17. 10.1210/jc.2003-030330 · DOI
  18. 10.1038/sj.ijir.3901205 · DOI
  19. 10.2165/00003495-200363200-00004 · DOI · Paper page
  20. 10.1016/j.eururo.2004.05.008 · DOI
  21. 10.1159/000019919 · DOI
  22. 10.1111/j.1464-410X.2010.09687.x · DOI
  23. Eardley I., 2002, Int J Clin Pract, 56, 300, 10.1111/j.1742-1241.2002.tb11260.x · DOI
  24. 10.1111/j.1743-6109.2011.02504.x · DOI
  25. 10.2147/TCRM.S80353 · DOI · Paper page
  26. 10.1046/j.1464-410X.1998.0820s1034.x · DOI
  27. 10.1056/NEJM199210223271701 · DOI
  28. 10.1111/j.1524-4733.2005.00074.x · DOI
  29. Health Canada, 2012, Finasteride (Proscar, Propecia) and Dutasteride (Avodart, Jalyn): May Increase the Risk of High-Grade Prostate Cancer
  30. 10.1016/j.urology.2010.03.015 · DOI
  31. 10.1016/S0960-0760(99)00030-8 · DOI
  32. Imperato-McGinley J., 1992, J Clin Endocrinol Metab, 75, 1022
  33. 10.1016/S0022-5347(05)00041-8 · DOI
  34. 10.1111/j.1464-410X.2006.06448.x · DOI
  35. 10.1152/ajpendo.00451.2005 · DOI
  36. 10.1093/jnci/djm117 · DOI
  37. 10.1124/dmd.109.027870 · DOI
  38. 10.1002/pros.10284 · DOI
  39. 10.1016/j.urology.2005.05.001 · DOI
  40. 10.1111/j.1464-410X.2004.05154.x · DOI
  41. 10.1056/NEJM199802263380901 · DOI · Paper page
  42. 10.1056/NEJMoa030656 · DOI
  43. McConnell J., 1992, J Clin Endocrinol Metab, 74, 505
  44. 10.1111/j.1464-410X.2006.06102.x · DOI · Paper page
  45. 10.1007/s11934-004-0047-1 · DOI
  46. 10.1016/j.juro.2006.10.055 · DOI
  47. McVary K., 2010, American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH)
  48. 10.1016/j.juro.2006.11.037 · DOI · Paper page
  49. 10.1038/sj.ijir.3901522 · DOI · Paper page
  50. Meibohm B., 1997, Int J Clin Pharmacol Ther, 35, 401
  51. 10.1111/j.1464-410X.2005.05485.x · DOI
  52. 10.1111/j.1442-2042.2010.02614.x · DOI
  53. 10.1016/j.eursup.2010.04.001 · DOI
  54. 10.1038/clpt.2009.265 · DOI
  55. 10.1046/j.1464-410X.1998.00868.x · DOI
  56. National Center for Biotechnology (2015a) PubChem Compound Database: CID = 110635. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/110635 (accessed 18 November 2015).
  57. National Center for Biotechnology (2015b) PubChem Compound Database: CID = 57363. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/57363 (accessed 18 November 2015).
  58. 10.1111/j.1464-410X.2011.10195.x · DOI
  59. 10.1016/j.eururo.2012.01.013 · DOI
  60. 10.1016/j.eururo.2011.08.005 · DOI
  61. 10.1016/j.beem.2008.01.016 · DOI
  62. Roehrborn C., 2005, Rev Urol, 7, S3
  63. 10.1016/S0090-4295(02)01905-2 · DOI · Paper page
  64. Roehrborn C., 2015, Int J Urol, 22, 582, 10.1111/iju.12741 · DOI
  65. 10.1016/j.juro.2008.06.079 · DOI · Paper page
  66. 10.1016/j.urology.2011.03.063 · DOI
  67. Roehrborn C., 2009, Eur Urol, 55, 461, 10.1016/j.eururo.2008.10.037 · DOI
  68. 10.1016/S0002-9149(03)00824-5 · DOI
  69. 10.1146/annurev.bi.63.070194.000325 · DOI · Paper page
  70. 10.1002/(SICI)1096-8628(19960503)63:1<223::AID-AJMG39>3.0.CO;2-O · DOI
  71. 10.1016/j.eururo.2008.01.075 · DOI
  72. 10.1016/0090-4295(94)90068-X · DOI
  73. Sussman D., 2004, J Am Osteopath Assoc, 104, S11
  74. 10.1111/j.1464-410X.2010.09204.x · DOI
  75. 10.1097/01.ju.0000091804.20183.81 · DOI
  76. 10.1016/j.urology.2007.10.051 · DOI
  77. 10.2165/00003495-199957040-00008 · DOI · Paper page
  78. 10.1172/JCI119074 · DOI

Cited by

See all 18

Metadata

Authors
Olesovsky, C., & Kapoor, A.
Affiliations
  • McMaster University, Hamilton, ON, Canada
  • McMaster Institute of Urology, 50 Charlton Avenue, G344 Mary Grace Wing, Hamilton, ON, Canada L8N 4A6
Venue
Therapeutic Advances in Urology
Publisher
SAGE Publications
Published
2016-05-26
Volume
8
Issue
4
Pages
257-271
ISSN
  • 1756-2872
  • 1756-2880
DOI
10.1177/1756287216650132
Cited by
18
References
0
Language
en
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia. https://app.cochat.ai/papers/10.1177/1756287216650132
The paper
Olesovsky, C., & Kapoor, A. (2016). Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia. Therapeutic Advances in Urology. https://doi.org/10.1177/1756287216650132

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.